262.22MMarket Cap-7615P/E (TTM)
5.100High4.540Low222.73KVolume4.610Open4.540Pre Close1.09MTurnover0.87%Turnover RatioLossP/E (Static)52.97MShares9.69052wk High1.03P/B127.10MFloat Cap3.73052wk Low--Dividend TTM25.68MShs Float14.710Historical High--Div YieldTTM12.34%Amplitude1.450Historical Low4.909Avg Price1Lot Size
TScan Therapeutics Stock Forum
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...
Benzinga· 2 mins ago
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
NEWS
TScan Therapeutics Announces Closing of Upsized Public Offering
$Forza X1 (FRZA.US)$
No comment yet